Mor­phoSys out-li­cens­es two an­ti­bod­ies to se­cre­tive ARCH biotech as it push­es for­ward with lead Con­stel­la­tion work

Mor­phoSys is part­ner­ing and in­vest­ing in a se­cre­tive ARCH-backed biotech as it con­tin­ues re­or­ga­niz­ing the pipeline fol­low­ing a $1.7 bil­lion June 2021 buy­out of Con­stel­la­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER